Biotage AB (publ) (BITGF)
ValueMarkers Composite Index
56% below intrinsic value ($3)
Biotage AB (publ) (BITGF) — VMCI valuation read
Biotage AB (publ) sits at VMCI 61/100, with the Healthcare sector median at 50. That 11-point spread is the first thing to note on BITGF: it tells the reader the composite is favorable before any single ratio is examined, and the mid-cap tier sets the comparison set.
Form 4 disclosures on BITGF are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.
**Investor frame.** The Value read on BITGF: BITGF trades at 18.0x earnings, 0% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp. The Risk read: net debt to EBITDA of -0.5x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.
BITGF rose 0.8% over the trailing 7 days, with a -23.5% read on a 30-day basis.
Biotage AB (publ) provides separation technologies in the areas of organic and analytical chemistry, biomolecules, and industrial scale up applications. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, and work-up products; flash systems and flash system accessories; normal, reversed, and speciality phase cartridges; plasmid purification solutions; and metal scavengers and reagents, as well as accessories and spare parts. It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables and systems; protein purification solutions, including antibody and tagged proteins purification, automation systems, and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, and government authorities and academic institutions, as well as clinical, forensic, and academic laboratories. It operates in 70 countries, which include Americas, Europe, the Middle East, Africa, and Asia Pacific. Biotage AB (publ) was founded in 1969 and is headquartered in Uppsala, Sweden.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.